Advances in systemic immune-inflammation index in peripheral blood of elder patients with gastrointestinal cancer

doi:10.3877/cma.j.issn.2095-8757.2019.04.008

Abstract

Abstract:

With the increasing degree of population aging, cancer rates are increasing among the elderly. The symptoms are often hidden, which is not easy to be detected at an early stage. Besides, different biological characteristics between the elder and the younger people make the prognostic judgment become more challenging. Therefore, it is important to search a simple and powerful prognostic index. The systemic immune inflammation index (SII), as an evaluation index of systemic inflammatory response, has been proved to be related with the prognosis in elder patients with digestive system neoplasm. The mechanism might be out of balance with pro-tumor factors and anti-tumor factors in the body under the state of tumor. After the body got out of balance, neutrophils and platelets increased, lymphocytes reduced, SII elevated. In addition, the joint detection of SII and other biomarkers, such as prognostic nutritional index, albumin-bilirubin score, carbohydrate antigen 19-9, can increase the prognostic efficacy of patients with cancer. SII could be easy obtained, easy and simple to handle, low cost and popularizing in clinical practice easily. This review summarizes the relationship of SII and gastrointestinal cancer in elder patients, wich is aimed at providing a reference for further SII research.

Key words: Systemic immune inflammation index, Gastrointestinal cancer, Inflammation, Prognosis

Jiabao Huang, Yu Sang, Xiaoqing Quan, Cuntai Zhang. Advances in systemic immune-inflammation index in peripheral blood of elder patients with gastrointestinal cancer[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2019, 06(04): 35-39.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2019.04.008

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2019/V06/I04/35

References 43

[1]	Takanori K, Bin-Zhi Q, Pollard JW. Immune cell promotion of metastasis[J]. Nature Reviews Immunology, 2015, 15(2):73-86.
[2]	郭亮，吴炅.肿瘤患者外周血免疫细胞在疗效预测及预后价值中的研究进展[J].中华乳腺病杂志(电子版)，2018，12(5)：299-301.
[3]	李婵，吴远鹏，吴吉进，等.SII预测恶性实体肿瘤预后的研究进展[J].实用医院临床杂志，2018，15(3)：252-254.
[4]	Bo H, Xin-Rong Y, Yang X, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(23):6212-6222.
[5]	周文杰，吴骏，王琦，等.评估术前系统免疫炎症指数与贲门癌患者预后的相关性[J].中国医药生物技术，2016，11(6)：510-514.
[6]	Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(43):75381-75388.
[7]	Hong X, Cui B, Wang M, et al. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer[J]. Tohoku J Exp Med, 2015, 236(4):297.
[8]	Lolli C, Basso U, Derosa L, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib[J]. Oncotarget, 2016, 7(34):54564-54571.
[9]	Xianchun M, Qian C, Yuying L, et al. Determinant roles of gender and age on SII, PLR, NLR, LMR and MLR and their reference intervals defining in Henan, China: A posteriori and big-data-based[J]. J Clin Lab Anal, 2018, 32(2). doi: 10.1002/jcla.22228.
[10]	Jingeng L, Xuan X, Chao Z, et al. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma[J]. Eur J Cardiothorac Surg, 2012, 41(3):e7.
[11]	Wang L, Wang C, Wang J, et al. A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2017, 143(10):1-10.
[12]	耿晓如，张鑫君，李连涛，等.系统免疫炎症指数与老年食管癌预后的关系[J].徐州医科大学学报，2017，39(12)：779-782.
[13]	Huang L, Liu S, Lei Y, et al. Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection[J]. Oncotarget, 2016, 7(28):44185-44193.
[14]	Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Cancer Manag Res, 2017, 9:9849-867.
[15]	Wang K, Diao F, Ye Z, et al. Prognostic value of systemic immune-inflammation index in patients with gastric cancer[J]. Chin J Cancer, 2017, 36(1):75.
[16]	Cha C, Fong Y, Jarnagin WR. Predictors and patterns of recurrence after resection of hepatocellular carcinoma[J]. J Am Coll Surg, 2003, 197(5):753-758.
[17]	Hongyuan F, Jun Z, Jianye C, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients after liver transplantation for hepatocellular carcinoma within hangzhou criteria[J]. Cell Physiol Biochem, 2018, 47(1):293-301.
[18]	Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022.
[19]	Yang Z, Zhang J, Lu Y, et al. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization[J]. Oncotarget, 2015, 6(40):43090-43098.
[20]	Conroy G, Salleron J, Belle A, et al. The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib[J]. Oncotarget, 2017, 8(56):95853-95864.
[21]	Passardi A, Scarpi E, Cavanna L, et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer[J]. Oncotarget, 2016, 7(22):33210-33219.
[22]	Ming-Yue T, Zhong-Hong W, Meng-Hui Z, et al. Prognostic value of the systematic immune-inflammation index among patients with operable colon cancer: A retrospective study[J]. Medicine (Baltimore), 2018, 97(45):e13156.
[23]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[24]	Gerd J, Elisabeth SG, Daniel W, et al. Systemic Immune-Inflammation Index (SII) predicts poor survival in pancreatic cancer patients undergoing resection[J]. J Gastrointest Surg, 2019. doi: 10.1007/s11605-019-04187-z.
[25]	Nicole A, Marie Louise BNB, Laura Chloe W, et al. The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer[J]? EMBO J, 2015, 34(17):2219-2236.
[26]	Tanaka Y, Ito S, Isobe K. Vancomycin-sensitive bacteria trigger development of colitis-associated colon cancer by attracting neutrophils[J]. Sci Rep, 2016, 6: 23920.
[27]	Houghton AM, Rzymkiewicz DH, Gregory AD, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth[J]. Nat Med, 2010, 16(2): 219-223.
[28]	Simon T, Hanan N, Craig M. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth[J]. Semin Cancer Biol, 2013, 23(3):149-158.
[29]	Mishalian, Inbal, Bayuh, et al. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties;during tumor progression[J]. Cancer Immunol Immunother, 2013, 62(11):1745-1756.
[30]	Ma XM, Sun X, Yang GW, et al. The platelet-to-lymphocyte ratio as a predictor of patient outcomes in ovarian cancer: a meta-analysis[J]. Climacteric, 2017, 20(5):448-455.
[31]	Yan MJ, Jurasz P. The role of platelets in the tumor microenvironment: From solid tumors to leukemia[J]. Biochim Biophys Acta, 2016, 1863(3):392-400.
[32]	Weber MR, Zuka M, Lorger M, et al. Activated tumor cell integrinαvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream[J]. Thromb Res, 2016, 140(Suppl 1:S27-S36.
[33]	Yibo G, Wei G, Songhua C, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma[J]. J Cancer, 2019, 10(14):3188-3196.
[34]	Valerie C, Jinmiao C, Deming L, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma[J].Gut, 2012, 61(3):427-438.
[35]	Jiang D, Liu Y, Hao W, et al. Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma[J]. Sci Rep, 2017, 7:44823.
[36]	Riccardo C, Paolo P, Emanuele C, et al. Nutritional support in cancer patients: A position paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE) [J]. J Cancer, 2016, 7(2):131-135.
[37]	Hongdian Z, Xiaobin S, Peng R, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma[J]. J Cell Physiol, 2019, 234(2):1794-1802.
[38]	Johnson PJ, Sarah B, Chiaki K, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6):550-558.
[39]	Ji F, Fu S, Guo Z, et al. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection[J]. Oncotarget, 2016, 7(44):72276-72289.
[40]	Casadei Gardini A, Foschi FG, Conti F, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals[J]. Dig Liver Dis, 2019, 51(5):681-688.
[41]	Zhe H, Fang L. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis[J]. Tumour Biol, 2014, 35(8):7459-7465.
[42]	Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal[J]. J Gastrointest Oncol, 2012, 3(2):105-119.
[43]	Zhang K, Hua YQ, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer[J].J Transl Med, 2019, 17(1):30.

Please choose a citation manager

Content to export